Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells

BACKGROUND: Chronic myeloid leukemia (CML) pathogenesis is mainly driven by the oncogenic breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) fusion protein. Since BCR-ABL displays abnormal constitutive tyrosine kinase activity, therapies using tyrosine kinase inhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lernoux, Manon, Schnekenburger, Michael, Losson, Hélène, Vermeulen, Koen, Hahn, Hyunggu, Gérard, Déborah, Lee, Jin-Young, Mazumder, Aloran, Ahamed, Muneer, Christov, Christo, Kim, Dong-Wook, Dicato, Mario, Bormans, Guy, Han, Byung Woo, Diederich, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236970/
https://www.ncbi.nlm.nih.gov/pubmed/32430012
http://dx.doi.org/10.1186/s13148-020-00839-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236970/
https://www.ncbi.nlm.nih.gov/pubmed/32430012
http://dx.doi.org/10.1186/s13148-020-00839-z

Ejemplares similares